Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732796 · ClinicalTrials.gov registry record · Phase 3
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 470
- Enrollment target
NCT01732796 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 470 participants.
The verdict
NCT01732796, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 470 participants
- Enrollment target
Study Summary
The aim of the study is to confirm efficacy of treatment for 16 and 24 weeks in chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
Interventions
- DRUG Ribavirin (RBV)
- DRUG BI 207127
- DRUG BI 201335 (Faldaprevir)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732796
The ClinicalTrials.gov registry entry for NCT01732796 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin (RBV) is the first listed.
NCT01732796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732796 about?
NCT01732796 is a clinical study titled "IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1". The aim of the study is to confirm efficacy of treatment for 16 and 24 weeks in chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
What is the current status of trial NCT01732796?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2012-12. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01732796?
The interventions under investigation include: Ribavirin (RBV) (DRUG), BI 207127 (DRUG), BI 201335 (Faldaprevir) (DRUG).
Who is sponsoring clinical trial NCT01732796?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.